

## DAY ONE WORKSHOPS



**21 June 2025** (Saturday)



**Sapphire 1, Dusit Thani Abu Dhabi, UAE**

### Unlocking the Power of Targeting CLDN 18.2; Zolbetuximab Role in LA Unresectable mGastric/GEJ Adenocarcinoma Workshop



**11:30 - 13:00 GST**

Supported by



11:30 - 11:45	New Horizon; Zolbetuximab in Management of Advanced Gastric/GEJ Cancer Moderator: <b>Dr. Aref Chehal, UAE</b> Speaker: <b>Dr. Dina Hamza, UAE</b>
11:45 - 12:00	CLDN18.2; The new targeted reflex Biomarker in Gastric/GEJ Cancer Moderator: <b>Dr. Husam Marashi, UAE</b> Speaker: <b>Dr. Rawia Mohamed, UAE</b>
12:00 - 12:15	UAE local experience in Management of Advanced Gastric/GEJ Cancer Moderator: <b>Dr. Husam Marashi, UAE</b> Speaker: <b>Dr. Shaheenah Dawood, UAE</b>
<b>Targeted Therapy Vs Immunotherapy Debate in Management of Advanced Gastric/GEJ Cancer; Biomarker Overlap</b> Moderators: Dr. Husam Marashi, UAE   Dr. Dalia Elshorbagy, UAE	
12:15 - 12:25	Expression: CPS 1-10% (In Favor of IO) <b>Dr. Syed Tirmazy, UAE</b>
12:25 - 12:35	Use of Zolbetuximab in CLDN 18.2 +ve GC with PDL1 (In Favor of Zolbe) <b>Dr. Hassan Jaafar, UAE</b>
12:35 - 13:00	<b>Full Panel Discussion</b>
13:00	<b>End of Workshop</b>

### PI3King the Right Path: Tailoring Care for HR+ Breast Cancer Workshop



**14:30 - 15:30 GST**

Supported by



14:30 - 14:40	Evolving landscape of PI3K/AKT inhibition <b>Dr. Emad Dawoud, UAE</b>
14:40 - 14:50	Identifying patients who can benefit from PI3Ki/AKTi <b>Dr. Bassel Jallad, UAE</b>
14:50 - 15:00	INAVO120 Phase III trial final overall survival (OS) analysis <b>Dr. Jawaher Ansari, UAE</b>
15:00 - 15:10	Sharing our first INAVO120 patients in UAE <b>Dr. Saeed Rafii, UAE</b>
15:10 - 15:30	Panel Discussion Moderator: <b>Dr. Saeed Rafii, UAE</b> Panelists: <b>Dr. Emad Dawoud, UAE   Dr. Bassel Jallad, UAE   Dr. Hassan Shahryar, UAE   Dr. Dina Hamza, UAE</b>



### Utilising ADCs to Improve Outcomes in Patients with Triple-Negative Breast Cancer Workshop



15:50 - 17:00 GST

Supported by  
 GILEAD  
Oncology

15:50 - 16:10	Current Paradigm in mTNBC <b>Dr. Hassan Jaafar, UAE</b>
16:10 - 16:20	Momentum in mTNBC: Interpreting Efficacy Evidence from ASCO 2025 <b>Dr. Hassan Jaafar, UAE</b>
16:20 - 16:40	Panel Discussion: New data, New Question mTNBC after ASCO <b>Panelists: Dr. Emad Dawoud, UAE   Dr. Anwar Alnouri, Kuwait   Dr. Dina Hamza, UAE   Dr. Husam Marashi, UAE</b>
16:40 - 16:50	Momentum in mTNBC: Interpreting Safety Evidence from ASCO 2025 <b>Dr. Hassan Jaafar, UAE</b>
16:50 - 17:00	Panel Discussion: Balancing Innovation and Safety: Navigating the Safety Seas of ADCs in Breast Cancer Treatment <b>Panelists: Dr. Faisal Alterkait, Kuwait   Dr. Dalia Elshorbagy, UAE   Dr. Bassel Jallad, UAE   Dr. Fathi Azribi, UAE</b>

### Shaping the Future of HR+/HER2- mBC Care Post-ASCO Workshop



17:00 - 18:00 GST

Supported by  
 AstraZeneca

17:00 - 17:05	Opening and Objectives <b>Moderator: Dr. Hassan Jaafar, UAE</b>
17:05 - 17:15	The Landscape Shift: Update on Treatment for HR+/HER2- mBC <b>Dr. Husam Marashi, UAE</b>
17:15 - 17:25	Redefining Endocrine Resistance: When and How to Act <b>Dr. Carlos Barrios, Brazil</b>
17:25 - 17:35	Q&A <b>All Speakers and Panellists</b>
17:35 - 17:45	Evolving ADCs Evidence <b>Prof. Gregory Vidal, USA</b>
17:45 - 17:55	Monday Morning Clinic - From Data to Daily Practice <b>Moderator: Dr. Husam Marashi, UAE</b> <b>Panelists: Dr. Emad Dawoud, UAE   Dr. Aref Chehal, UAE   Dr. Dina Hamza, UAE   Dr. Anwar Alnouri, Kuwait   Dr. Faisal Alterkait, Kuwait   Prof. Gregory Vidal, USA   Dr. Carlos Barrios, Brazil</b>
17:55 - 18:00	Q&A and Closing Remarks <b>All Speakers and Panellists</b>

# DAY TWO WORKSHOPS



22 June 2025 (Sunday)



Sapphire 1, Dusit Thani Abu Dhabi, UAE

## Optimizing Treatment Approaches in the Management of Resectable NSCLC Workshop



09:30 - 10:30 GST

Supported by



09:30 - 09:35	Introduction and Opening Moderator: <b>Dr. Syed Tirmazy, UAE</b>
09:35 - 10:05	Optimizing Treatment Approaches in the Management of Resectable NSCLC <b>Dr. Maximilian Hochmair, Austria</b>
10:05 - 10:30	Panel Discussion Moderator: <b>Dr. Syed Tirmazy, UAE</b> Panellists: <b>Dr. Usman Ahmad, UAE   Dr. Fathi Azribi, UAE   Dr. Dina Hamza, UAE   Dr. Saeed Rafii, UAE   Dr. Aref Chehal, UAE   Dr. Puja Gaur Khaitan, UAE   Dr. Emad Dawoud, UAE   Dr. Dalia Elshorbagy, UAE</b>

## Transforming the Landscape in the NSCLC First Line Setting Workshop



11:00 - 12:00 GST

Supported by



11:00 - 11:05	Welcome and Introduction Chairperson: <b>Dr. Emad Dawoud, UAE</b>
11:05 - 11:25	The Evolvment in the EGFRm NSCLC Upfront Setting & Impact of OS on TTT Decision From the Clinical Trial to the Clinical Practice <b>Dr. Saeed Rafii, UAE</b>
11:25 - 11:40	From the Clinical Trial to the Clinical Practice <b>Dr. Hassan Shahryar, UAE</b>
11:40 - 11:55	Round Table Discussion <b>Panel: All Speakers</b>
11:55 - 12:00	<b>Take Away Messages</b>